Annex II — Financial tender Financial Evaluation  Title:  Reference:  Lot:  Tenderer (name): Vaccine Effectiveness, Burden and Impact Studies of COVID-19 and Influenza OJ/2021/DPR/12924 Assessment of COVID-19 vaccine effectiveness among healthcare workers The table below is automatically filled in from the first sheet. It is not editable. The scenario in the table is only meant for evaluation purposes and does not constitute a commitment on the part of ECDC to request this volume of services. The reference price below must not exceed the estimated maximum budget for this contract: € 21'000'000 Please print/upload BOTH SHEETS (Financial tender and Financial evaluation). Unit price at  coordination level Unit price at study  site level Expected  repetition(s) of  deliverable  Expected Number of  study sites  Total price (unit price x  scenario) € 0 4 € 0 € 0 40 € 0 € 0 4 € 0 € 0 16 € 0 € 0 2 € 0 € 0 8 € 0 € 0 1 € 0 € 0 1 € 0 € 0 2 € 0 € 0 2 € 0 € 0 1 12 € 0 € 0 46 12 € 0 € 0 46 € 0 € 0 12 € 0 € 0 4 € 0 € 0 6 € 0 € 0 16 € 0 € 0 8 € 0 € 0 4 € 0 € 0 4 € 0 € 0 1 € 0 € 0 1 € 0  Deliverables DL 2.2.5 Regular epidemiological data update. Priceincludes work forcefor  data collection for thecountry at local level.  DL 2.1.1 Annual work plan for thelot, kick-off teleconferencewith ECDC and  minutes provided DL 2.1.2 Minutes of themonthly teleconferences between ECDC and the  contractor DL 2.1.3 Onlineannual meeting (approximately 60 participants) DL 2.1.4 Onlinetechnical meeting (approximately 30 participants) DL 2.1.5 Organisation of a faceto facemeeting, including meeting report DL 2.1.6 Reports on progress during each specific contract DL 2.1.7 Report/Standard Operating Procedures to transfer knowledgegained  through theproject  DL 2.2.1 Updateof EU/EEA Protocol for a study on vaccineeffectiveness among  health careworkers DL 2.2.2 Proposed list of sites joining thestudy  DL 2.2.3 Report describing all participating sites with standard templateacross  study sites DL 2.2.4 Hospital/ sitespecific Standard Operating Procedures to implement the  EU/EEA protocol. Cost includes initial investment in the setting up the study at  site/hospital level.  DL 2.2.6 Regular laboratory data update. Estimated priceon up to 3000  participants.* DL 2.2.7 Regular descriptiveand analytical report on results of thestudy DL 2.3.1 Annual epidemiological descriptiveand analytic report DL 2.3.2 Draft manuscript inclusiveopen access publication fee DL 2.3.3 Scientific materials for outputs related to health careworker study DL 2.4.1 Site-specific training/visit (In principleonly virtual trainings/ visits are  foreseen, If travel requested by ECDC costs will be reimbursed see contract  article I.5.3)  DL 2.4.2 Training workshop for study sites / information sharing workshop DL 2.4.3 Report on capacity building DL 2.5.1 Validation study DL 2.5.3 Evaluation of study site/hospital study specific implementation Page 5 of 15